Nodular regenerative hyperplasia of the liver after IL-2 therapy in an HIV-infected patient

This publication has 11 references indexed in Scilit:

• Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection
  Blood, 2004
• Nadir CD4+ T Cell Count Predicts Response to Subcutaneous Recombinant Interleukin-2
  Clinical Infectious Diseases, 2003
• A Randomized Trial of High‐ versus Low‐Dose Subcutaneous Interleukin‐2 Outpatient Therapy for Early Human Immunodeficiency Virus Type 1 Infection
  The Journal of Infectious Diseases, 1999
• Toxicity of Subcutaneously Administered Recombinant Human Interleukin-2 in Rats
  Toxicological Sciences, 1998
• Interleukin-2-induced hepatic injury involves temporal patterns of cell adhesion in the microcirculation.
  American Journal of Physiology-Gastrointestinal and Liver Physiology, 1997
• Controlled Trial of Interleukin-2 Infusions in Patients Infected with the Human Immunodeficiency Virus
  New England Journal of Medicine, 1996
• The role of cytokines, adhesion molecules, and chemokines in interleukin-2-induced lymphocytic infiltration in C57BL/6 mice.
  Journal of Clinical Investigation, 1996
• Increases in CD4 T Lymphocytes with Intermittent Courses of Interleukin-2 in Patients with Human Immunodeficiency Virus Infection — A Preliminary Study
  New England Journal of Medicine, 1995
• Treatment with anti-IL-2 antibodies reduces hepatic pathology and eosinophilia in Schistosoma mansoni-infected mice while selectively inhibiting T cell IL-5 production.
  The Journal of Immunology, 1992
• Hepatic vascular disease and portal hypertension in polycythemia vera and agnogenic myeloid metaplasia: A clinicopathological study of 145 patients examined at autopsy†
  Hepatology, 1990